A recent study has revealed that the commercialization of cannabis significantly increases its usage and is associated with rising mental health issues, contrasting with the effects of decriminalization and strict regulation. Conducted by an international team of researchers, the study examined cannabis policies from 2000 to 2025 across various countries, highlighting the implications of different regulatory approaches.

Commercialization and Its Consequences
The research indicates that in regions where cannabis is commercially sold, such as the United States and Canada, there is a notable increase in the number of users and the potency of the drug. This rise has been accompanied by a surge in hospital visits for psychosis and other mental health problems linked to cannabis use. Tom Freeman, a professor of psychology at the University of Bath and the study's lead author, emphasized that the findings present a clear distinction between commercial sales and more regulated or decriminalized environments.

Decriminalization's Limited Impact
In contrast, countries that have decriminalized cannabis, including various nations in Europe, Africa, Oceania, and Asia, reported little to no significant change in usage rates or psychiatric illnesses. Uruguay, the first country to fully legalize cannabis in 2013, has maintained strict state control over its market, allowing registered adults to purchase the drug from pharmacies or social clubs. The experience in these regions suggests that decriminalization does not inherently lead to increased consumption or health issues.

Policy Recommendations
Freeman noted that the study's results could serve as a guiding framework for policymakers contemplating cannabis decriminalization or regulation. He pointed out that the dynamics of a for-profit cannabis industry, similar to those of alcohol and tobacco, present unique challenges. The profit motive can lead to the promotion of cheaper and higher potency products, which may exacerbate usage and associated health risks.

The UK Context
In the United Kingdom, cannabis remains classified as a Class B drug, with severe penalties for possession. A report from the London Drugs Commission last year recommended decriminalizing recreational possession, citing disproportionate targeting of black individuals in drug-related searches. The report's findings align with the study's conclusions, suggesting a need for a reevaluation of cannabis policies in light of emerging evidence.

Wrap-up
The study underscores the complexities surrounding cannabis regulation and its impact on public health. As more countries consider altering their cannabis laws, the distinction between commercial sales and regulated decriminalization will be crucial in shaping future policies. Understanding the potential ramifications of these approaches is essential for mitigating health risks associated with cannabis use.

Sources
theguardian.com

@hoju-korean.com Editorial Team